Table 1.

Patient and tumor characteristics

Specimen description	Stage	Age (years)	TNM	Nuclear grade	ER	PR	p53 status	HER2/neu
Initial sample
43 DCIS (pure)	0	37	T3N0M0	ND	-	-	+	ND
44 DCIS (pure)	0	44	ToN0M0	2 and 3	+	+	-	+
46 DCIS (pure)	0	43	T2N0M0	3	+	+	-	+ (3+)
48 DCIS (pure)	0	52	T2N0M0	3	+	+	-	+ (3+)
49 DCIS (pure)	0	58	TicN0M0	3 (High grade)	-	-	-	+ (3+)
2 DCIS	IIa	48	T2N0M0	3	+	+	+	+
13 DCIS	IIa	75	T2N0M0	2	+	+	+	+ (2+)
25 DCIS	IIa	34	T2N0M0	3	+	+	+	+ (3+)
33 DCIS	I	38	T1cN0M0	3	+	-	-	-
45 DCIS	I	55	T1N0M0	3	-	-	+	+ (3+)
66 DCIS	IIIb	44	T4bN1M0	3	+	+	+	- (1+)
69 DCIS	IIb/IIIa	57	T2N1M0/pT2N2M0	2	+	+	ND	+ (2+)
75 DCIS	IIb	43	pT2N0M0	IDC 2/DCIS 3	-	-	+	+ (3+)
85 DCIS	I	73	T1cN0M0 pT3N0M0	2	+	+	-	+ (2+)
86 DCIS	ND	46	T2N1M0	3	+	+	+	+ (2+)
87 DCIS	IIa	48	T2N1M0	3	-	-	-	+ (2+)
1 IDC	IIa	45	T2N0M0	2	-	-	-	+ (3+)
3 IDC	IIa	43	T1cN0M0	3	+	-	-	+ (3+)
24 IDC	IIa	54	T2N0M0	3	+	+	+	+ (3+)
50 IDC	III b	71	T4N2M0	3	+	+	+	+ (2+)
51 IDC	II a	43	initial T2N0M0	3	-	ND	ND	+ (3+)
53 IDC	III a	43	T2N2M0	3	+	+	ND	+ (2+)
56 IDC	I	ND	ND	ND	ND	ND	ND	ND
80 IDC	IIa	44	pT1cpN1M0	3	+	+	-	-
81 IDC	IIb	31	T2N1M0	3	-	-	+	+ (3+)
83 IDC	IIa	48	T2N0M0	2	+	+	-	+ (2+)
Independent group of DCIS/IDC samples
1 DCIS	ND	58	T1N0M0	3	+	+	+	+ (2+)
2 DCIS	ND	40	T1N1M0	3	+	+	-	+ (2+)
3 DCIS	ND	27	T1N0M0	1 (Low grade)	ND	ND	ND	ND
4 DCIS	ND	53	ND	3 (High grade)	+	+	+	+ (2+)
5 DCIS	ND	51	T1N0M0	2	+	+	ND	+ (2+)
6 DCIS	III a	54	T3N1M0	3 (High grade)	-	-	ND	ND
8 DCIS	ND	52	T2N1M0	3	-	-	+	+ (3+)
9 DCIS	ND	38	T1N1M0	3 (High grade)	-	-	+	- (1+)
3 DCIS	ND	39	T2N0M0	ND	+	+	+	-
8 DCIS	ND	49	T2N0M0	ND	+	+	ND	-
15 DCIS	II b	69	T2N1M0	ND	+	+	ND	+ (2+)

Unless otherwise stated, 'DCIS' means in situ component of DCIS-IDC. DCIS, ductal carcinoma in situ; DCIS-IDC, ductal carcinoma in situ with co-existing invasive ductal carcinoma; ER, estrogen receptor; IDC, invasive ductal carcinoma; ND, not determined; PR, progesterone receptor; TNM, tumor size, nodal status and metastasis.